Cancer research across Africa: a comparative bibliometric analysis.
cancer
health services research
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
09
06
2022
accepted:
29
08
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
15
11
2022
Statut:
ppublish
Résumé
Research is a critical pillar in national cancer control planning. However, there is a dearth of evidence for countries to implement affordable strategies. The WHO and various Commissions have recommended developing stakeholder-based needs assessments based on objective data to generate evidence to inform national and regional prioritisation of cancer research needs and goals. Bibliometric algorithms (macros) were developed and validated to assess cancer research outputs of all 54 African countries over a 12-year period (2009-2020). Subanalysis included collaboration patterns, site and domain-specific focus of research and understanding authorship dynamics by both position and sex. Detailed subanalysis was performed to understand multiple impact metrics and context relative outputs in comparison with the disease burden as well as the application of a funding thesaurus to determine funding resources. African countries in total published 23 679 cancer research papers over the 12-year period (2009-2020) with the fractional African contribution totalling 16 201 papers and the remaining 7478 from authors from out with the continent. The total number of papers increased rapidly with time, with an annual growth rate of 15%. The 49 sub-Saharan African (SSA) countries together published just 5281 papers, of which South Africa's contribution was 2206 (42% of the SSA total, 14% of all Africa) and Nigeria's contribution was 997 (19% of the SSA total, 4% of all Africa). Cancer research accounted for 7.9% of all African biomedical research outputs (African research in infectious diseases was 5.1 times than that of cancer research). Research outputs that are proportionally low relative to their burden across Africa are paediatric, cervical, oesophageal and prostate cancer. African research mirrored that of Western countries in terms of its focus on discovery science and pharmaceutical research. The percentages of female researchers in Africa were comparable with those elsewhere, but only in North African and some Anglophone countries. There is an imbalance in relevant local research generation on the continent and cancer control efforts. The recommendations articulated in our five-point plan arising from these data are broadly focused on structural changes, for example, overt inclusion of research into national cancer control planning and financial, for example, for countries to spend 10% of a notional 1% gross domestic expenditure on research and development on cancer.
Identifiants
pubmed: 36356985
pii: bmjgh-2022-009849
doi: 10.1136/bmjgh-2022-009849
pmc: PMC9660667
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCI NIH HHS
ID : K08 CA230170
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMJ Glob Health. 2021 Oct;6(10):
pubmed: 34706882
BMJ Open. 2021 Oct 24;11(10):e052560
pubmed: 34690110
Lancet. 2017 Feb 25;389(10071):871-880
pubmed: 27814964
Glob Public Health. 2022 Oct;17(10):2547-2559
pubmed: 34520317
BMC Int Health Hum Rights. 2010 Oct 13;10:24
pubmed: 20942937
BMJ Glob Health. 2019 Oct 18;4(5):e001853
pubmed: 31750000
Scientometrics. 2016;106:105-117
pubmed: 26798161
Br J Anaesth. 2018 Oct;121(4):813-821
pubmed: 30236243
Lancet Oncol. 2020 Apr;21(4):e185-e224
pubmed: 32240612
Health Res Policy Syst. 2016 Mar 17;14:20
pubmed: 26983405
Lancet Oncol. 2022 Jun;23(6):e251-e312
pubmed: 35550267
Lancet Glob Health. 2019 Oct;7(10):e1375-e1387
pubmed: 31537368
PLoS One. 2019 Jan 16;14(1):e0198117
pubmed: 30650079
J Womens Health (Larchmt). 2012 Mar;21(3):355-62
pubmed: 22132763
Lancet Oncol. 2013 Apr;14(4):e158-67
pubmed: 23561747
JCO Glob Oncol. 2021 May;7:802-810
pubmed: 34077269
PLoS One. 2020 Apr 27;15(4):e0232077
pubmed: 32339197
BMJ Open. 2016 Aug 23;6(8):e011390
pubmed: 27554102
J Empir Res Hum Res Ethics. 2015 Apr;10(2):169-84
pubmed: 25819759
BMC Med Res Methodol. 2016 May 20;16:56
pubmed: 27206853
J Am Heart Assoc. 2015 Apr 02;4(4):
pubmed: 25836056
BMJ Glob Health. 2019 Mar 4;4(2):e001047
pubmed: 30899571
Eur J Cancer. 2018 Sep;100:75-84
pubmed: 30014883
Nat Rev Cancer. 2008 May;8(5):398-403
pubmed: 18385682
Tomography. 2021 Nov 15;7(4):801-803
pubmed: 34842845
JCO Glob Oncol. 2020 Aug;6:1264-1275
pubmed: 32762563
Ecancermedicalscience. 2019 Jul 25;13:938
pubmed: 31552111
Ecancermedicalscience. 2020 Sep 18;14:ed106
pubmed: 33144883
Lancet Oncol. 2021 Aug;22(8):e369-e376
pubmed: 34216541
Malawi Med J. 2010 Sep;22(3):65-70
pubmed: 21977849
Front Oncol. 2021 Apr 15;11:650117
pubmed: 33937056
Health Res Policy Syst. 2021 Jan 22;19(1):11
pubmed: 33482839